OverviewChartProfileKey statisticsFinancialsNewsTraderScreen

INDIVIOR PLC DL 0,50/  GB00BN4HT335  /

Lang & Schwarz
2024-07-28  7:02:51 PM Chg. 0.000 Volume Bid7:02:51 PM Ask7:02:51 PM Market Capitalization Dividend Y. P/E Ratio
11.700EUR 0.00% -
Turnover: -		 11.700Bid Size: - 12.000Ask Size: - 1.61 bill.EUR - -
GlobeNewswire 07-01 Addex Shareholders Approve All Resolutions at Annual General Meeting
GlobeNewswire 06-06 Addex Therapeutics Reports Q1 2024 Financial Results and Provides Corporate Update
GlobeNewswire 06-05 Addex Convenes Annual General Meeting 2024
GlobeNewswire 05-31 Addex Therapeutics to Release Q1 2024 Financial Results and Host Conference Call on June 6, 2024
GlobeNewswire 05-08 Addex to Present at Bio€quity Europe 2024
GlobeNewswire 04-29 Addex Provides Update on ADX71149 Phase 2 Epilepsy Study
GlobeNewswire 04-19 Addex to Present at the Swiss Biotech Day 2024
GlobeNewswire 04-18 Addex Therapeutics Reports Full Year 2023 Financial Results and Provides Corporate Update
GlobeNewswire 04-11 Addex Therapeutics to Release Full-Year 2023 Financial Results and Host Conference Call on April 18,...
GlobeNewswire 04-03 Addex and Perceptive Launch Neurosterix with $63 Million to Accelerate Development of Allosteric Mod...
GlobeNewswire 03-14 Addex to Present at the Bio-Europe Spring 2024 Conference
GlobeNewswire 03-05 Aquestive Therapeutics Reports Full Year 2023 Financial Results and Provides Business Update
GlobeNewswire 01-31 Addex Enters into At-The-Market ADS Offering Agreement with H.C. Wainwright & Co. LLC.
GlobeNewswire 01-18 Adial Announces Appointment of Tony Goodman as Chief Operating Officer
GlobeNewswire 01-09 Addex to Present at the Swiss Equities Baader Conference
GlobeNewswire 01-05 Addex to Present at Biotech Showcase™ 2024
GlobeNewswire 2023-12-14 Addex Creates Treasury Shares
GlobeNewswire 2023-11-29 Addex Reports Q3 2023 Financial Results and Provides Corporate Update
GlobeNewswire 2023-11-28 Addex Convenes Extraordinary General Meeting
GlobeNewswire 2023-11-23 Addex Therapeutics to Release Third Quarter 2023 Financial Results and Host Conference Call on Novem...
GlobeNewswire 2023-11-14 Addex ADX71149 Epilepsy Phase 2 Study Completes Recruitment of Patients
GlobeNewswire 2023-11-08 Addex Regains Nasdaq Listing Compliance
GlobeNewswire 2023-11-02 Addex Announces Participation in the Bio-Europe 2023 Conference
Newsfile Corp 2023-10-31 Pharma and Biotech Business Development Leaders to Discuss Psychedelics Partnering at Wonderland
GlobeNewswire 2023-10-20 Addex Completes ADS Ratio Change